Alembic Pharma USFDA nods: $1,869m Levothyroxine 2026

What the latest USFDA decisions mean for Alembic

Alembic Pharmaceuticals has reported multiple regulatory milestones from the United States Food and Drug Administration (USFDA), reinforcing its steady expansion in the US generics market. The latest update includes a final approval for Levothyroxine Sodium Tablets USP across several strengths and a tentative approval for Darolutamide Tablets. Separately, the company has also disclosed other USFDA approvals across therapeutic areas such as neurology, psychiatry, ophthalmology, migraine, Parkinson’s disease, and hypertension.

For Indian pharma investors, USFDA ANDA outcomes matter because the US remains the largest profit pool for many generic-focused manufacturers. Each approval expands addressable opportunities, but the commercial impact depends on factors such as competition, pricing, launch timing, and any remaining patent or exclusivity constraints.

Final approval: Levothyroxine Sodium Tablets (25 mcg to 300 mcg)

Alembic Pharmaceuticals received USFDA final approval for its abbreviated new drug application (ANDA) for Levothyroxine Sodium Tablets USP. The approved strengths range from 25 mcg to 300 mcg. The company said the product is therapeutically equivalent to AbbVie’s Synthroid Tablets.

Levothyroxine is commonly used for hypothyroidism, a condition where the thyroid gland does not produce enough hormones. Therapeutic equivalence to a reference listed drug is a key point in the US generic pathway because it establishes that the generic can be substituted under relevant rules.

IQVIA has estimated the market size for Levothyroxine Sodium Tablets at US$ 1,869 million for the 12 months ending March 2026.

Market size snapshot for Levothyroxine

The Levothyroxine opportunity highlighted by Alembic is large in absolute terms, based on the cited IQVIA estimate. However, market size alone does not indicate how much any one manufacturer will sell, since volumes can be split across multiple approved competitors and affected by price erosion.

What is clear from the disclosure is that Alembic now has the regulatory clearance needed to market the product in the US, subject to its own launch plans.

Tentative approval: Darolutamide Tablets 300 mg (Nubeqa equivalent)

In a separate regulatory update, Alembic Pharmaceuticals said it has received tentative USFDA approval for Darolutamide Tablets, 300 mg. The company described it as a generic equivalent to the branded Nubeqa Tablets.

The US market for Darolutamide Tablets was estimated at US$3,155 million (converted from US$ 3.155 billion) in the company’s disclosure. Alembic also explained what tentative approval means: the application meets USFDA standards, but final approval is dependent on the resolution of existing patent or exclusivity protections.

How tentative approval differs from final approval

A final approval allows a company to market the product in the US, while a tentative approval indicates the product is approvable from a quality and scientific standpoint but cannot yet be marketed due to remaining legal barriers. In practical terms, the tentative decision is a meaningful step in readiness, but commercialisation is still contingent on timing around patents or exclusivities.

This distinction is important for investors tracking potential launches, because a tentative approval does not automatically translate into near-term revenue.

Portfolio scale: Alembic’s cumulative ANDA approvals

Along with the Levothyroxine update, Alembic said it now has 239 total ANDA approvals. This number provides context on the company’s long-running focus on the US generics pipeline and its ability to execute filings and approvals across multiple dosage forms and therapies.

A high cumulative count does not, by itself, reveal the revenue contribution from each approval. But it does show continuity in regulatory throughput, which is often a key driver of product breadth in the US market.

Other USFDA approvals mentioned across therapies

The broader set of approvals referenced includes:

• Final USFDA approval for Lamotrigine orally disintegrating tablets in multiple strengths. Alembic said this ANDA is therapeutically equivalent to GlaxoSmithKline LLC’s reference listed drug Lamictal orally disintegrating tablets. The product is positioned as a generic medication for seizures.
• Approval for a generic version of Carbidopa, Levodopa and Entacapone tablets used in the treatment of Parkinson’s disease.
• Final approval for Loteprednol Etabonate and Tobramycin ophthalmic suspension (0.5 percent/0.3 percent) in 5 mL and 10 mL packs, used for an eye infection. Alembic said it was granted Competitive Generic Therapy (CGT) designation for this application and is eligible for 180 days of CGT exclusivity upon commercialisation.
• Approval for Sumatriptan Injection (4 mg/0.5 ml and 6 mg/0.5 ml) single-dose autoinjector system.
• Approval for Carbamazepine Tablets USP, 200 mg, described as therapeutically equivalent to the reference listed drug Tegretol Tablets, 200 mg (Novartis). The disclosure notes its use as an anticonvulsant and also for pain associated with trigeminal neuralgia. IQVIA estimated the market size at US$ 32 million for the 12 months ending December 2024.
• Final approval for Paliperidone extended-release tablets indicated for the treatment of schizophrenia.

Market and stock context mentioned in the update

The data provided also included a stock snapshot: on 6 Feb, 2026 at 15:53, Alembic Pharmaceuticals’ share price was ₹797.65. The day’s move was -1.58 (with 12.80% also stated), with an intraday range of ₹776.20 to ₹808.00. The 52-week range cited was ₹725.20 to ₹1,107.90.

While stock moves can reflect many variables, the key business takeaway from the regulatory disclosures is the continued flow of USFDA outcomes across multiple products.

Key facts table

Why these approvals matter for the US generics business

The Levothyroxine final approval adds a high-value molecule category to Alembic’s US lineup based on the cited market size. The Darolutamide tentative approval shows progress on a much larger referenced market, but the company has explicitly flagged that final approval depends on patent or exclusivity outcomes.

The additional approvals cited across neurology, psychiatry, ophthalmology, migraine, and Parkinson’s disease underline a broad therapeutic spread. The CGT designation for the ophthalmic suspension is also notable because the company has stated eligibility for 180 days of CGT exclusivity upon commercialisation, which can be relevant to early-launch economics.

Conclusion

Alembic Pharmaceuticals’ latest disclosures point to continued execution in US filings and approvals, led by final approval for Levothyroxine Sodium Tablets and tentative approval for Darolutamide Tablets. The company’s stated total of 239 ANDA approvals provides scale context, while the next key milestone for Darolutamide will be the resolution of patent or exclusivity protections needed for final approval.